Synlogic, Inc. (SYBX)
NASDAQ: SYBX · Real-Time Price · USD
1.506
+0.006 (0.39%)
Aug 14, 2025, 11:17 AM - Market open
Company Description
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Contact Details
Address: PO Box 30 Winchester, Massachusetts 01890 United States | |
| Phone | 617 659 2802 |
| Website | synlogictx.com |
Stock Details
| Ticker Symbol | SYBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001527599 |
| CUSIP Number | 87166L100 |
| ISIN Number | US87166L2097 |
| Employer ID | 26-1824804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mary Beth Dooley | Principal Executive Officer and Principal Financial Officer |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. James J. Collins Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | SCHEDULE 13G/A | Filing |
| Feb 21, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 5, 2024 | 8-K | Current Report |